The Pharma industry in India is seeking government intervention to control export of Ossein, to overcome gelatine shortage.
Subscribe to our email newsletter
Gelatine is required for the production of hard and soft gel capsules in the country. Ossein is a semi-finished product of gelatine.
The European Commission has announced new norms for countries coming under the World Organization for Animal Health’s, reporting the least threat categories for bovine spongiform encephalopathy (BSE), the pharmabiz reported.
India is categorized as safe source as per BSE and hence the exports of crushed bones or Ossein, than value-added products like gelatine, gelatine capsules or finished formulations from India were increased.
The manufacturing process of Ossein involves putting crushed animal bones through a purification process for a period of 45-60 days, which generates a lot of effluent.